The study found that non-alcoholic fatty liver is a key gene for liver cancer
-
Last Update: 2020-12-17
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Hong Kong Chinese University announced on the 23rd, the university's research team found that high-angle sacranene cyclooxidase (SQLE) induced non-alcoholic fatty liver disease and its associated liver cancer, and found that tebifen can effectively inhibit the growth of non-alcoholic fatty liver-induced liver cancer cells.
according to HKU, non-alcoholic fatty liver is an important cause of liver cancer, but the medical profession is not clear about the mechanism, and there is a lack of effective treatment and preventive drugs. At present, about 30% of adults in Hong Kong have non-alcoholic fatty liver disease.
research team genetically sequenced 18 tumor tissues of liver cancer induced by non-alcoholic fatty liver disease with normal liver tissue and found that SQLe was significantly higher in patients with such liver cancer, while patients with high SQLE liver cancer had shorter lifetimes.
SQLE is a key enzyme for cholesterol synthesis in the body. The team used genetic engineering to build experimental mouse models with high SQL liver cells. The results showed that the risk of liver cancer in experimental mice with SQL gene transformation increased significantly, which proved that SQLe was the carcinogenic factor of non-alcoholic fatty liver cancer.
researchers also found that antifalal drugs that inhibit SQL, called tebifen, can be a way to treat and prevent non-alcoholic fatty liver cancer, providing a new direction for the treatment of this type of liver cancer.
Yu Jun, a professor in the Department of Internal Medicine and Drug Therapy at the Hong Kong University Of Medicine who led the study, said SQLE played a key role in non-alcoholic fatty liver cancer and would continue to study the effectiveness of tebifen in treating and preventing such liver cancer, hoping to translate the results into clinical applications in the future.
was published on April 18 at an internationally renowned
conference. (Source: Xinhua News Agency, Zhang Yashi)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
